WHO grants emergency usage listing for Covaxin
Covaxin has demonstrated 77.8% effectiveness against symptomatic COVID-19 and 65.2% protection against the new Delta variant
The Technical Advisory Group (TAG) of the World Health Organization (WHO), has recommended emergency use listing (EUL) status for Covaxin, a covid-19 vaccine developed by Bharat Biotech.
WHO is in the process of evaluating Covaxin’s clinical trial data for use of EUL. The TAG on October 26 had sought “additional clarifications” from the company for Covaxin to conduct a final “risk-benefit assessment” for EUL of the vaccine.
The TAG-EUL is an independent advisory group that provides recommendations to WHO on whether a Covid-19 vaccine can be listed for emergency use under the EUL procedure.
Covaxin has demonstrated 77.8% effectiveness against symptomatic Covid-19 and 65.2% protection against the new Delta variant.
Bharat Biotech’s Covaxin and AstraZeneca and Oxford University’s Covishield are the two widely used vaccines in India.